The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 01, 2024
Filed:
May. 22, 2019
Applicant:
Beigene, Ltd., Grand Cayman, KY;
Inventors:
Assignee:
BEIGENE, LTD., Grand Cayman, KY;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 31/337 (2006.01); A61K 31/454 (2006.01); A61K 31/706 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61K 31/337 (2013.01); A61K 31/454 (2013.01); A61K 31/706 (2013.01); A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01);
Abstract
The present disclosure provides antibodies and antigen-binding fragments thereof that bind to human OX40 (ACT35, CD134, or TNFRSF4), a pharmaceutical composition comprising said antibody, and use of the antibody or the composition for treating a disease, such as cancer. In particular, the anti-OX40 antibody of the present invention does not interfere with the binding of OX40-ligand to its receptor.